Berenberg Bank reiterated their buy rating on shares of Abcam (LON:ABC) in a report issued on Tuesday. They currently have a GBX 1,640 ($21.43) price target on the stock.

ABC has been the topic of several other research reports. JPMorgan Chase & Co. reiterated a neutral rating on shares of Abcam in a research report on Wednesday, January 2nd. Peel Hunt reissued a hold rating on shares of Abcam in a research note on Thursday, December 6th. Finally, Numis Securities reissued a hold rating on shares of Abcam in a research note on Tuesday, September 11th.

Shares of LON ABC opened at GBX 1,216 ($15.89) on Tuesday. Abcam has a 1 year low of GBX 9.73 ($0.13) and a 1 year high of GBX 1,290 ($16.86).

In other Abcam news, insider Suzanne Smith acquired 864 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The shares were acquired at an average price of GBX 1,219 ($15.93) per share, with a total value of £10,532.16 ($13,762.13). Also, insider Jonathan Simon Milner acquired 187,790 shares of the company’s stock in a transaction that occurred on Thursday, December 6th. The shares were acquired at an average cost of GBX 1,060 ($13.85) per share, for a total transaction of £1,990,574 ($2,601,037.50).

Abcam Company Profile

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

See Also: Treasury Bonds

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.